Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 271-178-7 | CAS number: 68516-75-6
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
![](https://echa.europa.eu/o/diss-blank-theme/images/factsheets/A-REACH/factsheet/print_toxicological-information.png)
Repeated dose toxicity: oral
Administrative data
- Endpoint:
- short-term repeated dose toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 17.9. - 5.11.2008
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: see 'Remark'
- Remarks:
- Guideline study conducted according to GLP. No analytical verification of test item stability and homogenity. No tables with individual data. No scoring system for severety of histopathology findings. Comparison to historical control data sometimes mentioned in the freetext, but no actual data provided.
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 009
- Report date:
- 2009
Materials and methods
Test guidelineopen allclose all
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 407 (Repeated Dose 28-Day Oral Toxicity Study in Rodents)
- Version / remarks:
- (1995)
- Deviations:
- yes
- Remarks:
- No analytical monitoring of test substance. Data for individual animals not reported.
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.7 (Repeated Dose (28 Days) Toxicity (Oral))
- Version / remarks:
- (2008)
- Deviations:
- yes
- Remarks:
- No analytical monitoring of test substance
- GLP compliance:
- yes
- Limit test:
- no
Test material
- Reference substance name:
- N,N'-phenylene-1,4-bis[4-[(2,5-dichlorophenyl)azo]-3-hydroxynaphthalene-2-carboxamide]
- EC Number:
- 223-460-6
- EC Name:
- N,N'-phenylene-1,4-bis[4-[(2,5-dichlorophenyl)azo]-3-hydroxynaphthalene-2-carboxamide]
- Cas Number:
- 3905-19-9
- Molecular formula:
- C40H24Cl4N6O4
- IUPAC Name:
- 3,3'-[(2,2'',5,5''-tetrachloro-1,1':4',1''-terphenyl-4,4''-diyl)bis(triaz-2-ene-3,1-diylcarbonyl)]di(2-naphthol)
- Test material form:
- solid: bulk
- Details on test material:
- - Name of test material (as cited in study report): C.I. Pigment Red 166
- Physical state: red powder
- Analytical purity:ca. 99%
- Impurities (identity and concentrations): water (up to 1%)
- Stability: 15 years
- Storage condition of test material: at room temperature
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Wistar
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: SPF breeding, VELAZ s.r.o., Kolec u Kladna, Czech Republic
- Age at study initiation: 6 -7 weeks
- Mean group weight range at study initiation: males, 182.20 - 183.24 g; females, 136.16 - 136.78 g
- Fasting period before study: the animals starved before blood collection for approximately 18 hours but they received drinking water ad libitum.
- Housing: 2-3 rats of the same sex in one plastic cage (40x25x20 cm) containing sterilised clean shavings of soft wood.
- Diet (e.g. ad libitum): sterilised complete peleted diet for rats and mice in SPF breeding (ST 1 BERGMAN) was offered ad libitum.
- Water (e.g. ad libitum): sterilised drinking water with a quality corresponding to Regulation No. 252/2004 Czech Coll. of Law (Health Ministry) was offered ad libitum.
- Acclimation period: at least 5 days
- Diet, water and bedding analysis for contaminants: the standard pelleted laboratory animal diet is analysed for nutrients (once a year) and each batch is microbiologically examined on a regular basis. Certificates of analysis of water (performed twice a year) also are available. Bedding (sterilised clean shavings of soft wood) are examined for bacteriological contaminants once a year. Analysis of diet, water and bedding, did not reveal any findings that could affect study integrity.
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22 +/- 3
- Humidity (%): 30 - 70
- Air changes (per hr): 15
- Photoperiod (hrs dark / hrs light): 12 / 12
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- olive oil
- Remarks:
- (Batch No.: L 701 151 and L 803 142; manufactured by Dr. Kulich Pharma s.r.o., Hradec Kralové, Czech Republic)
- Details on oral exposure:
- PREPARATION OF DOSING SOLUTIONS
The test substance is insoluble in many solvents. Low solubility of the test substance was declared by the Sponsor and it was also checked up during the substance identity verification. In this study the substance was found also insoluble in olive oil. Therefore the test substance was administered as an olive oil suspension. A suitable analytical method was not found for homogeneity and stability testing. Since undissolved particles of the test substance are easily visible in the application form, homogeneity was checked by eye (suspensions were mixed for 15 minutes by magnetic stirrer).The concentrations of suspensions at every dose level were adjusted to ensure the administration of 1 mL/100 g bw. The test substance suspension in olive oil was prepared daily and mixed for 15 minutes by magnetic stirrer just prior administration. The vehicle control group received olive oil in the same volume, without test substance.
TREATMENT
The treated and control groups were administered daily for the period of 28 days. Oral administration was chosen on the request of sponsor. The animals were treated 7 days per week at the specified time (8.00 - 10.00 am). - Analytical verification of doses or concentrations:
- no
- Details on analytical verification of doses or concentrations:
- No suitable analytical method was available for homogeneity and stability testing. Since undissolved particles of the test substance are easily visible in the application form, homogeneity was checked by eye (suspensions were mixed for 15 minutes by magnetic stirrer).
- Duration of treatment / exposure:
- 28 days
- Frequency of treatment:
- Once daily, 7 days per week
Doses / concentrationsopen allclose all
- Dose / conc.:
- 1 000 mg/kg bw/day (actual dose received)
- Dose / conc.:
- 400 mg/kg bw/day (actual dose received)
- Dose / conc.:
- 0.16 mg/kg bw/day (actual dose received)
- No. of animals per sex per dose:
- Five animals per sex and dose group
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- DOSE SELECTION RATIONALE
The doses were selected with respect to the results of a dose-range finding experiment.
SATELLITE GROUPS
A control (vehicle) satellite group as well as a 1000 mg/kg bw/day satellite group, each consisting of five animals per sex were added. These two groups were subjected to a treatment-free post exposure period of 14 days (i.e. day 29 to 42 of experiment).
Examinations
- Observations and examinations performed and frequency:
- CLINICAL OBSERVATIONS (GENERAL AND DETAILLED) AND MORTALITY
The animals were subjected to general clinical observation daily, during the administration period.
The animals were subjected to detailled clinical observation once prior test initiation and weekly thereafter. At the first part of observation behaviour of animals in the cage was monitored: posture, position of eyelids, tonic or clonic movements, piloerection, stereotypes or bizarre behaviour. The second part was the observation during removal from cage: reaction to handling, elasticity of skin, colour of mucous membranes, salivation, lacrimation, cleanliness of fur around foramina.
Check for mortality was done daily.
BODY WEIGHT
Body weight was recorded weekly.
FOOD CONSUMPTION
Food consumption was recorded weekly.
WATER CONSUMPTION
Water consumption was recorded twice a week
OPHTHALMOSCOPIC EXAMINATION
None
HAEMATOLOGY AND CLINICAL CHEMISTRY
Blood samples were collected on day 29 of study for the main groups and on day 43 for the satellite groups. The blood samples were collected from the orbital plexus under light ether narcosis into PVC test tubes containing anticoagulation systems.
Haematology analyser Coulter and Coagulometer were used for examination and the following parameters were considered: Total erythrocyte count RBC, Mean corpuscular volume MCV, Haematocrit HCT, Haemoglobin concentration HGB, Total leucocyte count WBC, Total platelet count PLT, Partial thromboplastin time APTT, Prothrombin time PT, Fibrinogen FIB, Granulocytes GRAN, Lymphocytes LYM, Monocytes MON.
The biochemical parameters were measured in the serum of the blood samples, which was obtained by centrifugation; the separated serum was collected individually. The following parameters were determined by automatic biochemical analysers: Glucose GLU, Cholesterol total T-Cho, Urea BUN, Bilirubin total T-Bil, Aspartate aminotransferase AST, Alanine aminotransferase ALT, Alkaline phosphatase ALP, Calcium Ca, Phosphorus IP, Protein total T-Pro, Protein albumin ALB, Creatinine Crea, Sodium Na, Potassium K, Chloride Cl.
URINALYSIS
Urine was collected on day 28 of study for the main groups and on day 42 for the satellite groups. For this purpose the rats were kept in metabolic cages and urine was collected for two hours. Immediately before entering metabolic cages the animals were administered with 2 mL/100 g bw of drinking water by gavage. The following parameters were considered: Volume, Colour, Cloud, Odour, Glucose GLU, Protein PRO, Bilirubin BIL, Urobilinogen URO, pH, specific gravity, Blood BLD, Ketones KET, Nitrites NIT, Leucocytes LEU.
NEUROBEHAVIOURAL EXAMINATION
This observation was done at the end of administration period at main groups or at the end of recovery period at satellite groups. During functional examination, the sensory reactivity on auditory, visual, proprioceptive stimuli and pupillary reflex were evaluated and motor activity assessment was conducted. Moreover the individual observations of grip strength were performed using dynamometer. Measurements were made on pectoral legs, pelvis legs, and all four legs; grip power was expressed in Newtons. - Sacrifice and pathology:
- At the end of study the experimental animals were narcotised and sacrificed by cutting the neck spine and medulla. The cranial, thoracic and abdominal cavities were examined and then the organs were collected for weighing, gross pathology and histopathology.
ORGAN WEIGHTS
The absolute and relative weights of liver, kidneys, adrenals, gonads (testes or ovaries), epididymides or uterus, thymus, spleen, brain, pituitary gland and heart were recorded/calculated.
GROSS PATHOLOGY
A revision of the external surface of the body, of all orifices and the cranial, thoracic and abdominal cavities were carried out. Organs for consequent pathological examination were taken out and stored in containers with fixative (buffered 4% formaldehyde).
HISTOPATHOLOGY
Tissue specimens fixed in 4% buffered formaldehyde were processed by routine paraffin technique and stained by hematoxyline-eosine. Cryotome sections of liver and kidneys were stained by oil red for neutral lipids. Samples of following tissues and organs were considered for histopathology: Adrenal glands, Ovaries, Aorta, Pancreas, Brain (- cerebellum, mid-brain, cortex), Jejunum, Ileum, Caecum, Pituitary gland, Cervix of uterus, Prostate gland, Coagulation gland, Salivary glands (mandibular), Colon, Sciatic nerve, Duodenum, Seminal vesicles, Epididymides, Skeletal muscle, Female mammary gland area, Skin, Femur (bone marrow), Spinal cord (midthoracic), Heart, Spleen, Stomach, Testes, Kidneys, Thymus, Liver, Thyroid, Lungs, Trachea, Lymph nodes (mesenteric, paraaortal), Urinary bladder, Oesophagus, Uterus, all gross lesions. - Statistics:
- The ANOVA test - Analysis of Variance (QC.Expert 2.5) at significance level 0.05 was used for the statistical analysis. This statistical analysis was used for the results of haematology, blood chemistry, urinalysis, biometry of organs and body weight. Control group with vehicle was compared with three treated groups and satellite control with vehicle was compared with the satellite treated group. The results statistically significant on probability level 0.05 were indicated.
Results and discussion
Results of examinations
- Clinical signs:
- no effects observed
- Mortality:
- no mortality observed
- Body weight and weight changes:
- no effects observed
- Food efficiency:
- no effects observed
- Ophthalmological findings:
- not examined
- Haematological findings:
- no effects observed
- Clinical biochemistry findings:
- no effects observed
- Urinalysis findings:
- no effects observed
- Behaviour (functional findings):
- no effects observed
- Organ weight findings including organ / body weight ratios:
- no effects observed
- Gross pathological findings:
- effects observed, treatment-related
- Description (incidence and severity):
- In 2 of 5 males of the high dose group (1000 mg/kg bw), enlarged paraortal nodes and in one of them enlarged mesenterial nodes with changed colour were recorded.
- Histopathological findings: non-neoplastic:
- effects observed, treatment-related
- Description (incidence and severity):
- reactive hyperplasia of paraaortic lymph nodes (grade not specified) in 2/5 males at 1000 mg/kg bw
- Details on results:
FOOD CONSUMPTION
No adverse effect on dietary intake and food efficiency was observed. It was noticed that the application of the test substance caused temporary colouring of the chyme but without marked effect on function of digestive tract. For details, see table below.
WATER CONSUMPTION
Water consumption decreased in both sexes treated with 1000 mg/kg bw/day during the application period. However, urinalysis revealed no changes of concern, thus indicating that the finding was of no toxicological relevance. For details, see table below.
HAEMATOLOGY
All parameters were within the historical control range. Occasionally parameters showed a statisical difference to the control group. There was however no dose-response relationship. Consdering that all parameters were within the historical control range, the changes are considered to be incidental and to be not related to the treatment.
CLINICAL CHEMISTRY
All parameters were within the historical control range. Occasionally parameters showed a statisical difference to the control group. There was however no dose-response relationship. Consdering that all parameters were within the historical control range, the changes are considered to be incidental and to be not related to the treatment.
The measured concentration of urea was below the historic control almost in all females at the middle dose level. Due to absence of changed hepatic parameters or histopathological changes in liver or kidneys, this effect was considered to be of no toxicological importance.
URINALYSIS
Urinalysis showed significantly decreased pH values only in females at the end recovery period. At the end application period there were detected only sporadic presences of protein, cloud or urobilinogen at all dose levels. No microscopic changes were found which could be associated to these sporadic changes; thus they were considered to be of no toxicological importance.
NEUROBEHAVIOUR
Functional observation evidenced no effect of the test substance.
ORGAN WEIGHTS
Sporadic significant changes in weight affecting brain and pituitary gland only were noticed at the end of the recovery period. Differences in absolute or relative weight of liver were sporadically recorded in males and females but were not associated to microscopic changes in this organ. Thus, differences in incidence of findings between control and treatment groups were considered to be of no toxicological significance.
GROSS PATHOLOGY AND HISTOPATHOLOGY
Pathological examination revealed possibly treatment changes in two of the males at the end of application period. Enlarged paraortal nodes (2 of 5 males, none in females) and enlarged mesenterial nodes with changed colour (1 of five males, none in females) were recorded at the highest dose level of 1000 mg/kg bw/day. Histopathology showed reactive hyperplasia of unknown severety of the paraaortic lymph nodes in the two males of the high dose group. No individual data is included in the report, but this information could later be retrieved directly from the CRO. Incidence of reactive hyperplasia in control animals was reported to be zero to two per study.
No neoplastic findings were recorded by histopathological examination.
Effect levels
open allclose all
- Dose descriptor:
- NOEL
- Effect level:
- 400 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male
- Basis for effect level:
- clinical signs
- food consumption and compound intake
- other: 2 males affected: Enlarged paraortal nodes with reactive hyperplasia (n =2) and enlarged mesenterial nodes with changed colour (n=1) at of 1000 mg/kg bw/day.
- Dose descriptor:
- NOEL
- Effect level:
- 1 000 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- female
- Basis for effect level:
- body weight and weight gain
- food consumption and compound intake
Target system / organ toxicity
- Critical effects observed:
- not specified
Any other information on results incl. tables
Body weight data:
Mean group body weight (g) for the male rats |
||||
Main study (28 days treatment) |
||||
Test group |
0 mg/kg bw/d |
160 mg/kg bw/d |
400 mg/kg bw/d |
1000 mg/kg bw/d |
Day 0 |
182.54 |
182.28 |
183.24 |
182.22 |
Week 1 |
225.46 |
223.52 |
217.92 |
219.02 |
Week 2 |
258.36 |
258.26 |
249.50 |
252.76 |
Week 3 |
284.16 |
283.78 |
272.12 |
280.18 |
Week 4 |
306.16 |
306.86 |
289.38 |
305.74 |
Recovery groups (28 days treatment + 14 days recovery) |
||||
Day 0 |
182.20 |
- |
- |
182.80 |
Week 1 |
221.30 |
- |
- |
222.02 |
Week 2 |
251.34 |
- |
- |
255.34 |
Week 3 |
275.84 |
- |
- |
284.62 |
Week 4 |
295.84 |
- |
- |
309.72 |
Week 5 |
311.14 |
- |
- |
325.14 |
Week 6 |
320.48 |
- |
- |
338.26 |
Mean group body weight (g) for the female rats |
||||
Main study (28 days treatment) |
||||
Test group |
0 mg/kg bw/d |
160 mg/kg bw/d |
400 mg/kg bw/d |
1000 mg/kg bw/d |
Day 0 |
136.58 |
136.66 |
136.60 |
136.72 |
Week 1 |
155.26 |
156.12 |
154.42 |
156.46 |
Week 2 |
167.54 |
170.64 |
166.90 |
172.40 |
Week 3 |
178.06 |
179.50 |
175.14 |
180.98 |
Week 4 |
190.24 |
190.42 |
182.74 |
186.50 |
Recovery groups (28 days treatment + 14 days recovery) |
||||
Day 0 |
136.16 |
- |
- |
136.78 |
Week 1 |
152.42 |
- |
- |
156.98 |
Week 2 |
164.50 |
- |
- |
172.04 |
Week 3 |
175.98 |
- |
- |
181.92 |
Week 4 |
186.28 |
- |
- |
190.68 |
Week 5 |
190.76 |
- |
- |
199.04 |
Week 6 |
194.86 |
- |
- |
206.00 |
Food consumption data:
Mean food consumption (g/animal/day) for male and females rats |
||||||||
Main study (28 days treatment) |
||||||||
Test group |
0 mg/kg bw/d |
160 mg/kg bw/d |
400 mg/kg bw/d |
1000 mg/kg bw/d |
||||
Sex |
M |
F |
M |
F |
M |
F |
M |
F |
Week 1 |
21.09 |
13.84 |
19.43 |
14.77 |
18.47 |
12.68 |
17.76 |
13.57 |
Week 2 |
19.27 |
12.07 |
17.91 |
12.66 |
17.12 |
10.44 |
16.79 |
12.15 |
Week 3 |
18.53 |
11.46 |
16.92 |
11.67 |
16.15 |
10.44 |
16.95 |
11.30 |
Week 4 |
18.60 |
12.16 |
15.86 |
11.00 |
16.95 |
9.87 |
17.22 |
11.50 |
Recovery groups (28 days treatment + 14 days recovery) |
||||||||
Week 1 |
20.63 |
13.85 |
- |
- |
17.53 |
13.37 |
||
Week 2 |
18.49 |
12.18 |
- |
- |
17.61 |
11.57 |
||
Week 3 |
17.61 |
11.31 |
- |
- |
18.19 |
10.65 |
||
Week 4 |
18.19 |
11.51 |
- |
- |
18.32 |
11.34 |
||
Week 5 |
19.59 |
13.06 |
- |
- |
18.94 |
14.01 |
||
Week 6 |
19.87 |
13.09 |
- |
- |
20.29 |
13.74 |
Water consumption data:
Mean water consumption (mL/animal/day) for male and females rats |
||||||||
Main study (28 days treatment) |
||||||||
Test group |
0 mg/kg bw/d |
160 mg/kg bw/d |
400 mg/kg bw/d |
1000 mg/kg bw/d |
||||
Sex |
M |
F |
M |
F |
M |
F |
M |
F |
Week 1 |
40.00 |
31.71 |
37.43 |
33.14 |
36.86 |
32.00 |
36.57 |
32.29 |
Week 2 |
37.14 |
28.29 |
35.14 |
30.57 |
34.00 |
28.00 |
38.57 |
31.43 |
Week 3 |
39.43 |
32.86 |
39.14 |
34.57 |
38.00 |
31.71 |
36.29 |
33.71 |
Week 4 |
40.57 |
35.71 |
39.14 |
36.29 |
38.57 |
31.43 |
36.29 |
31.43 |
Recovery groups (28 days treatment + 14 days recovery) |
||||||||
Week 1 |
39.71 |
33.14 |
- |
- |
35.14 |
29.14 |
||
Week 2 |
36.57 |
28.00 |
- |
- |
34.57 |
27.71 |
||
Week 3 |
40.00 |
34.00 |
- |
- |
38.00 |
30.29 |
||
Week 4 |
40.57 |
34.29 |
- |
- |
36.29 |
30.57 |
||
Week 5 |
40.57 |
35.14 |
- |
- |
39.71 |
34.29 |
||
Week 6 |
40.57 |
32.29 |
- |
- |
37.14 |
30.86 |
Haematological data for females (means) | ||||||
dose group | 0 | 140 | 400 | 1000 | recovery 0 | recovery 1000 |
RBC (10 exp6/uL) | 6.57 | 6.87 | 6.72 | 6.82 | 7.03 | 6.9 |
MCV | 53.9 | 54.6 | 53.4 | 53.7 | 53.4 | 54.1 |
Haematocrit (%) | 35.6 | 37.5 | 35.9 | 36.6 | 37.6 | 37.2 |
Haemogloblin (g/100ml) | 12.6 | 13 | 12.7 | 13 | 13.3 | 13.2 |
WBC (1000 /uL) | 3.8 | 4.1 | 3.7 | 3.6 | 4.5 | 4.7 |
Platelets (1000 /uL) | 900 | 919 | 919 | 820 | 865 | 929 |
APTT (S) | 24 | 26 | 28 | 26 | 26 | 25 |
Protrombine Time (s) | 25 | 26 | 28 | 26 | 26 | 25 |
Fibrinogen (g/L) | 1.66 | 1.8 | 1.81 | 1.82 | 1.76 | 2.06 |
Granulocytes (%) | 6.5 | 5.6 | 6.8 | 4.5 | 5.4 | 6.4 |
Lymphocytes (%) | 86.9 | 87.1 | 81 | 87.6 | 86.3 | 84 |
Monocytes (%) | 6.6 | 7.3 | 12.1 | 7.9 | 8.2 | 9.6 |
Haematological data for males (means) | ||||||
dose group | 0 | 140 | 400 | 1000 | recovery 0 | recovery 1000 |
RBC (10 exp6/uL) | 6.65 | 7.01 | 7.94 | 6.83 | 7.08 | 7.26 |
MCV | 53.9 | 55.8 | 53.8 | 56.2 | 51.3 | 53.8 |
Haematocrit (%) | 35.8 | 38.9 | 37.7 | 38.3 | 37.6 | 39.2 |
Haemogloblin (g/100ml) | 12.5 | 13.3 | 13.2 | 13 | 13.3 | 13.5 |
WBC (1000 /uL) | 7.18 | 6.84 | 6.36 | 7.26 | 6.22 | 7.94 |
Platelets (1000 /uL) | 879 | 893 | 787 | 730 | 826 | 827 |
APTT (S) | 28.8 | 25.2 | 36.2 | 43.5 | 40.8 | 34.9 |
Protrombine Time (s) | 25 | 32.2 | 31.8 | 29.4 | 33 | 28.9 |
Fibrinogen (g/L) | 2.23 | 2.27 | 2.23 | 2.43 | 2.66 | 2.43 |
Granulocytes (%) | 9.56 | 7.56 | 6.5 | 5.7 | 7.6 | 9 |
Lymphocytes (%) | 83.7 | 86.3 | 85.1 | 87 | 80.7 | 81.8 |
Monocytes (%) | 6.8 | 6.1 | 8.4 | 7.3 | 11.5 | 9.2 |
Applicant's summary and conclusion
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
![ECHA](/o/diss-blank-theme/images/factsheets/A-REACH/factsheet/echa_logo.png)